A tiny fluid channel could sample living cancer cells without destroying tissue

MIT and Johns Hopkins researchers reported on September 24 a handheld tool that removes living cells from precise spots on already excised tissue while leaving much of that tissue intact. It could help researchers investigate early ovarian cancer, but it is not yet a screening device used inside patients.

Why living cells are hard to keep

Many high-grade serous ovarian cancers begin in the fallopian tubes, where the earliest lesions can be too small to sample easily. Standard pathology preserves removed tissue with chemicals and examines thin sections. That preserves its structure but kills the cells, preventing researchers from growing them or testing their behavior.

The new device uses a small microfluidic channel held against the tissue. A syringe sends fluid through it, creating a sideways force that detaches cells from a selected patch of surface. In a study published in the journal Device, the team collected viable cells from freshly excised fallopian-tube tissue and cultivated them.

This does not replace pathology. The point is to get living material from a known location while leaving the surrounding sample available for existing examination. The researchers say such cells could be grown into organoids or used to study how disease develops and, eventually, how an individual's cells respond to treatments.

The clinical gap remains wide

The team tested different cell types and found that collection could be tuned by changing the fluid's shear stress. That supports the idea that the approach may extend beyond ovarian tissue. It does not mean the same setting will work for every tissue, or that a clinician can already use the instrument during a routine appointment.

MIT says the likely first application involves tissue that has already been removed, partly because that would be a simpler regulatory path. Sampling inside a patient is a longer-term aspiration. Even on removed tissue, a useful diagnostic would need to show that it finds meaningful early changes reliably, without interfering with the established pathology process.

The odd engineering move here is gentle abrasion by flowing liquid: take cells alive, but keep the underlying specimen. The medical claim is deliberately smaller. Researchers now have a possible way to study early lesions and personalize experiments; they have not demonstrated that the device detects ovarian cancer earlier or improves survival.

The next evidence will come from validation on more patient samples and from testing whether the captured cells reveal information that conventional sections miss.